DM Tests

Physiological Regulation of Blood Glucose Homeostasis

  • Blood glucose concentration is maintained within a narrow physiological range of 70−100 mg/dL70-100\,\text{mg/dL} (4−6 mM4-6\,\text{mM}) in healthy individuals.

  • Deviations from this homeostatic range are categorized as:

    • Hyperglycaemia: Blood glucose elevation above the normal physiological threshold.

    • Hypoglycaemia: Blood glucose drop below the normal physiological threshold.

  • Maintenance of blood glucose levels depends on the balance between glucose entry into the circulation and glucose removal by tissues:

    • Sources of circulating glucose:

    • Diet: Ingestion, enzymatic digestion, and intestinal absorption of carbohydrates.

    • Hepatic glycogenolysis: Breakdown of stored liver glycogen into free glucose; serves as the primary endogenous glucose source during early fasting periods (12−18 hours12-18\,\text{hours}).

    • Gluconeogenesis: De novo synthesis of glucose from non-carbohydrate substrates including lactate, glycerol, and glucogenic amino acids (predominantly alanine); serves as the main endogenous glucose source during prolonged fasting or starvation (>18 hours>18\,\text{hours}).

    • Fates and utilization of circulating glucose:

    • Energy production: Cellular uptake and metabolic oxidation (glycolysis, tricarboxylic acid cycle, and oxidative phosphorylation).

    • Storage: Conversion to glycogen via glycogenesis in the liver and skeletal muscle, and conversion to fatty acids/triacylglycerols via lipogenesis in adipose tissue.

  • Endocrine regulation of glucose balance:

    • High blood glucose state (postprandial):

    • Pancreatic beta-cells stimulate insulin secretion.

    • Insulin promotes peripheral glucose uptake in skeletal muscle and adipose tissue.

    • Insulin enhances hepatic glycogenesis.

    • Insulin suppresses hepatic gluconeogenesis.

    • Net effect: Blood glucose decreases toward the normal range (70−100 mg/dL70-100\,\text{mg/dL} or 4−6 mM4-6\,\text{mM}).

    • Low blood glucose state (fasting/sleep):

    • Pancreatic alpha-cells stimulate glucagon secretion.

    • Glucagon stimulates hepatic glycogenolysis.

    • Glucagon stimulates hepatic gluconeogenesis.

    • Net effect: Blood glucose increases toward the normal homeostatic range.


Hormonal regulation of blood glucose homeostasis

Overview and Classification of Diabetes Mellitus

  • Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia secondary to defects in insulin secretion, insulin action, or both.

  • Chronic hyperglycaemia results in widespread long-term structural and functional organ damage, dysfunction, and failure.

  • Clinical sequelae and complications:

    • Diabetic retinopathy (leading cause of adult blindness).

    • Diabetic nephropathy (leading cause of end-stage renal disease).

    • Cardiovascular disease (myocardial infarction and stroke).

    • Diabetic neuropathy and peripheral vascular disease (leading causes of non-traumatic lower limb amputation).

  • Clinical classifications of diabetes:

    • Type 1 Diabetes Mellitus (T1DM):

    • Previously termed insulin-dependent diabetes mellitus (IDDM) or juvenile/childhood-onset diabetes.

    • Characterized by deficient insulin production resulting from autoimmune destruction of pancreatic beta-cells.

    • Absolute requirement for exogenous insulin therapy for survival.

    • Type 2 Diabetes Mellitus (T2DM):

    • Previously termed non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes.

    • Characterized by peripheral insulin resistance paired with a progressive relative defect in insulin secretion.

    • Gestational Diabetes Mellitus (GDM):

    • Any degree of glucose intolerance with onset or first recognition during pregnancy.

    • Blood glucose values are elevated above normal physiological levels but below established diagnostic thresholds for overt diabetes.

    • Other specific types of diabetes mellitus:

    • Genetic defects in beta-cell function (e.g., MODY) or insulin action.

    • Diseases of the exocrine pancreas (pancreatitis, trauma, pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis).

    • Endocrinopathies (Cushing syndrome, acromegaly, pheochromocytoma, glucagonoma, hyperthyroidism).

    • Drug- or chemical-induced diabetes: Glucocorticoids (prednisolone), antipsychotic medications (typical agents like haloperidol and chlorpromazine, as well as newer atypical antipsychotics).

  • Prediabetes:

    • Characterized by intermediate hyperglycaemia manifesting as Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT).

    • Not classified as a discrete disease entity, but represents a major risk state for developing overt Type 2 diabetes and cardiovascular disease.

    • Strongly associated with obesity, dyslipidemia (elevated triglycerides, reduced HDL), hypertension, and metabolic syndrome.

Risk Factors for Developing Diabetes Mellitus

  • Advancing age.

  • Metabolic syndrome components.

  • Documented history of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT).

  • Polycystic ovary syndrome (PCOS).

  • History of gestational diabetes mellitus (GDM) or delivery of a macrosomic infant weighing over 4 kg4\,\text{kg}.

  • Strong family history of diabetes mellitus (first-degree relatives).

  • Physical inactivity and sedentary lifestyle.

  • Established personal history of cardiovascular disease (CVD).

  • Elevated Body Mass Index (BMI≥25 kg/m2\text{BMI} \ge 25\,\text{kg/m}^2, or ≥23 kg/m2\ge 23\,\text{kg/m}^2 in Asian Americans).

  • Central (visceral/abdominal) obesity.

  • Systemic hypertension.

  • Abnormal serum lipid profile (hypertriglyceridemia, low HDL-cholesterol).

  • Elevated liver function tests (LFTs), often reflecting non-alcoholic fatty liver disease.

  • Pharmacotherapy with diabetogenic agents, including steroids (prednisolone) and antipsychotics (haloperidol, chlorpromazine, and atypical antipsychotics).

Fasting Blood Glucose (FBG) Test

  • Biochemical basis:

    • Reflects the homeostatic equilibrium between hepatic glucose production (HGP\text{HGP}) and peripheral glucose disposal during the fasting state.

    • Mathematically represented as:     Fasting Plasma Glucose=Hepatic Glucose Output−Peripheral Glucose Utilization\text{Fasting Plasma Glucose} = \text{Hepatic Glucose Output} - \text{Peripheral Glucose Utilization}

    • During the overnight fast, low circulating insulin combined with elevated glucagon drives hepatic glucose output via glycogenolysis and gluconeogenesis (utilizing alanine, other glucogenic amino acids, lactate, and glycerol).

    • Constant glucose utilization persists unabated in obligate glucose-dependent tissues (the brain, erythrocytes, and renal medulla).

  • Patient preparation protocol:

    • Complete fasting duration of 8−12 hours8-12\,\text{hours} (absolute minimum requirement of 8 hours8\,\text{hours}).

    • Nutritional stability: Patient must consume a balanced diet containing typical daily carbohydrate requirements for at least 2−3 days2-3\,\text{days} prior to specimen collection.

    • Pharmacological washout: Patient must avoid drugs known to modulate glucose metabolism for at least 2 days2\,\text{days} prior to testing.

  • Diagnostic reference intervals:

    • Normal: ≤100 mg/dL\le 100\,\text{mg/dL}.

    • Prediabetes (Impaired Fasting Glucose): 100−125 mg/dL100-125\,\text{mg/dL}.

    • Diabetes Mellitus: ≥126 mg/dL\ge 126\,\text{mg/dL}.


Blood glucose diagnostic thresholds for fasting state

Random Blood Glucose (RBG) Test

  • Biochemical basis:

    • Evaluates instantaneous glycaemic status and metabolic homeostasis without restriction on previous caloric intake.

    • Captures the real-time balance between circulating glucose inputs (dietary absorption, ongoing hepatic glycogenolysis, and gluconeogenesis) and circulatory clearance (insulin-mediated uptake into muscle and adipocytes, insulin-independent neural uptake, glycogenesis, and cellular oxidation).

  • Clinical testing parameters:

    • Specimen collection occurs at any time of day, entirely independent of the timing or content of the previous meal.

    • Reflects short-term glycaemic equilibrium and acute homeostatic regulatory capacity.

  • Diagnostic reference intervals:

    • Normal: 79−160 mg/dL79-160\,\text{mg/dL} (4.4−8.9 mmol/L4.4-8.9\,\text{mmol/L}).

    • Prediabetes: 160−200 mg/dL160-200\,\text{mg/dL} (8.9−11.1 mmol/L8.9-11.1\,\text{mmol/L}).

    • Diabetes Mellitus: ≥200 mg/dL\ge 200\,\text{mg/dL} (11.1 mmol/L11.1\,\text{mmol/L}).

Oral Glucose Tolerance Test (OGTT)

  • Clinical indications:

    • Diagnostic evaluation of non-pregnant adults exhibiting impaired fasting glucose.

    • Universal or risk-stratified screening of pregnant women between 24−28 weeks24-28\,\text{weeks} of gestation.

    • Assessment of functional physiological handling of a standard oral glucose challenge.

  • Standard procedure:

    • Patient observes an overnight fast lasting 8−12 hours8-12\,\text{hours}.

    • A baseline fasting venous blood sample is drawn for plasma glucose measurement.

    • The patient consumes a standardized oral glucose challenge consisting of 75 g75\,\text{g} of anhydrous glucose dissolved in water (glucose syrup) within 5 minutes5\,\text{minutes}.

    • A subsequent venous blood sample is drawn exactly 2 hours2\,\text{hours} post-ingestion.

  • Diagnostic cut-off values (2 hours2\,\text{hours} post-challenge):

    • Normal glucose tolerance: ≤140 mg/dL\le 140\,\text{mg/dL} (7.8 mmol/L7.8\,\text{mmol/L}).

    • Prediabetes (Impaired Glucose Tolerance): 140−199 mg/dL140-199\,\text{mg/dL} (7.8−11.0 mmol/L7.8-11.0\,\text{mmol/L}).

    • Diabetes Mellitus: ≥200 mg/dL\ge 200\,\text{mg/dL} (11.1 mmol/L11.1\,\text{mmol/L}).


Oral Glucose Tolerance Test response curves
  • Morphological interpretation of OGTT curves:

    • Normal response curve:

    • Fasting plasma glucose is within normal limits (≤100 mg/dL\le 100\,\text{mg/dL}).

    • Peak plasma glucose concentration occurs within the first hour (30−60 minutes30-60\,\text{minutes}).

    • The peak concentration does not breach the renal tubular threshold for glucose (160−180 mg/dL160-180\,\text{mg/dL}).

    • Plasma glucose declines rapidly, returning to baseline fasting levels by 2−2.5 hours2-2.5\,\text{hours}.

    • Urinalysis specimens collected concurrently show total absence of glucose and ketone bodies.

    • Diabetic curve (moderate to severe diabetes mellitus):

    • Fasting glucose is markedly elevated (≥126 mg/dL\ge 126\,\text{mg/dL}).

    • The peak glucose level is delayed, appearing between 1−1.5 hours1-1.5\,\text{hours} post-load.

    • Peak glucose concentration significantly exceeds the physiological renal threshold (160−180 mg/dL160-180\,\text{mg/dL}).

    • Blood glucose remains sustained and fails to return to baseline fasting concentrations within 2.5 hours2.5\,\text{hours}.

    • Glucosuria is present in urine aliquots, except in select cases of advanced chronic diabetic nephropathy or chronic nephritis presenting with an abnormally elevated renal threshold.

    • LAG curve (oxyhyperglycaemia):

    • Fasting baseline glucose is entirely normal.

    • Extremely rapid gastrointestinal absorption causes an exaggerated early spike within 30−60 minutes30-60\,\text{minutes}, exceeding the renal threshold (160−180 mg/dL160-180\,\text{mg/dL}) and producing transient glucosuria.

    • Subsequent insulin hypersecretion precipitates a rapid and complete descent back to baseline fasting concentrations or below by 2 hours2\,\text{hours}.

    • Etiologies: Hyperthyroidism, post-gastrectomy or post-gastroenterostomy states (accelerated gastric emptying), normal pregnancy, and very early-stage diabetes mellitus.

    • Renal glucosuria curve:

    • Plasma glucose trajectory remains completely normal throughout fasting, peak, and recovery phases.

    • Glucose appears in the urine due to a primary reduction in the tubular transport maximum for glucose reabsorption (TmG\text{TmG}), establishing an abnormally low renal threshold.

Postprandial Blood Glucose (PPBG) Test

  • Biochemical and clinical basis:

    • Evaluates peripheral post-challenge glucose handling and postprandial insulin secretory dynamics in response to mixed physiological meals.

    • In healthy individuals, endogenous insulin secretions normalize blood glucose levels within 2 hours2\,\text{hours}.

    • In diabetic individuals, impaired early-phase insulin release and peripheral insulin resistance result in protracted hyperglycaemic excursions.

  • Testing protocol:

    • Plasma glucose concentration is quantified exactly 2 hours2\,\text{hours} after consuming a standard meal.

    • Serves as an established clinical tool for monitoring glycemic management in patients with known diabetes and detecting postprandial hyperglycaemia.

  • Diagnostic reference intervals (2 hours2\,\text{hours} postprandial):

    • Normal: <140 mg/dL< 140\,\text{mg/dL} (7.8 mmol/L7.8\,\text{mmol/L}).

    • Impaired Glucose Tolerance (Prediabetes): 140−199 mg/dL140-199\,\text{mg/dL} (7.8−11.0 mmol/L7.8-11.0\,\text{mmol/L}).

    • Diabetes Mellitus: >200 mg/dL> 200\,\text{mg/dL} (11.1 mmol/L11.1\,\text{mmol/L}).


Postprandial blood glucose curve comparison

Glycated Haemoglobin (HbA1c\text{HbA}_{1c})

  • Biochemical mechanism:

    • Mediated by a slow, non-enzymatic, irreversible condensation reaction (Amadori rearrangement) between free glucose molecules and the N-terminal valine residue of the haemoglobin beta-chain.

    • Occurs continuously within erythrocytes throughout their circulating lifespan (≈120 days\approx 120\,\text{days}).

    • The final rate and degree of glycation are directly proportional to the ambient plasma glucose concentration and the temporal duration of erythrocyte exposure.

  • Clinical utility:

    • Serves as an objective index of mean integrated glycaemic concentration over the preceding 8−12 weeks8-12\,\text{weeks} (2−3 months2-3\,\text{months}).

    • Utilized for the definitive diagnosis of diabetes and routine longitudinal monitoring of long-term glycaemic management.

    • Requires standard peripheral venous blood collection; requires no patient fasting, caloric restriction, or specific acute preparation.


Mechanism of hemoglobin glycation
  • Diagnostic reference cut-offs:

    • Normal: <5.7%< 5.7\%.

    • Intermediate hyperglycaemia (Prediabetes): 5.7%−6.4%5.7\% - 6.4\%.

    • Diabetes Mellitus: ≥6.5%\ge 6.5\%.

  • Laboratory analytical methodologies:

    • High-Performance Liquid Chromatography (HPLC): Highest precision and accuracy; considered the analytical gold standard.

    • Immunoassays: Highly common in clinical laboratories and point-of-care testing systems.

    • Electrophoresis or Enzymatic Assays: Less common alternative laboratory methods.

  • Confounding clinical factors and analytical limitations:

    • Falsely elevated HbA1c\text{HbA}_{1c} readings:

    • Vitamin B12 deficiency anaemia.

    • Iron deficiency anaemia (delayed erythrocyte turnover).

    • Post-splenectomy states (prolonged erythrocyte survival).

    • Chronic kidney disease.

    • Chronic alcohol use disorder.

    • Normal pregnancy.

    • Falsely depressed HbA1c\text{HbA}_{1c} readings:

    • Acute or severe chronic blood loss (hemorrhage).

    • Chronic liver disease.

    • Exogenous erythropoietin administration (reticulocytosis/young red cell population).

    • Variable or unpredictable effects (falsely increased or decreased):

    • Haemoglobinopathies (e.g., HbS, HbC, HbE traits or thalassemias).

Diagnostic Confirmation and Screening Protocols

  • Criteria for confirming a diagnosis of diabetes:

    • In asymptomatic individuals: Two separate abnormal test results obtained from different occasions are mandatory for definitive diagnosis. This requires either repeating the identical test on a new blood sample without delay or performing an alternative validated diagnostic test.

    • In symptomatic individuals: A single abnormal test result is sufficient for diagnosis in the presence of classical symptoms of hyperglycaemia (polyuria, polydipsia, unexplained weight loss) accompanied by a random plasma glucose ≥200 mg/dL\ge 200\,\text{mg/dL} (11.1 mmol/L11.1\,\text{mmol/L}).

  • Screening protocols in asymptomatic adults:

    • Risk-based screening: Adults of any age who are overweight or obese (BMI≥25 kg/m2\text{BMI} \ge 25\,\text{kg/m}^2, or BMI≥23 kg/m2\text{BMI} \ge 23\,\text{kg/m}^2 in individuals of Asian American descent) presenting with one or more additional diabetes risk factors.

    • Universal screening: All individuals, regardless of risk profiles, should begin routine screening at age 45 years45\,\text{years}.

    • Retesting interval: If screening results are within normal limits, repeat testing is recommended at a minimum interval of every 3 years3\,\text{years}.

    • Screening modalities: Fasting plasma glucose, 2 hour2\,\text{hour} plasma glucose during a 75 g75\,\text{g} OGTT, and HbA1c\text{HbA}_{1c} possess equal diagnostic appropriateness.

    • Cardiovascular management: When prediabetes or diabetes is identified, evaluate and aggressively manage comorbid cardiovascular disease risk factors.

  • Screening protocols in children and adolescents:

    • Screen asymptomatic children and adolescents following the onset of puberty or after age 10 years10\,\text{years} who are overweight or obese (BMI>85th\text{BMI} > 85\text{th} percentile for age and sex, weight-for-height >85th> 85\text{th} percentile, or weight >120%> 120\% of ideal for height) combined with additional risk factors (maternal history of GDM, family history of T2DM, race/ethnicity, signs of insulin resistance).

  • Diagnostic approach for acute Type 1 Diabetes Mellitus:

    • In patients exhibiting acute clinical presentations of hyperglycaemia, fasting or random plasma glucose tests are preferred over HbA1c\text{HbA}_{1c} due to the rapid timeline of beta-cell loss.

    • Supporting diagnostics include evaluation of urinary glucose, urinary ketone bodies (acetoacetate), and quantification of pancreatic autoantibody panels (anti-GAD65, anti-IA-2, anti-insulin, and anti-ZnT8 autoantibodies).

Gestational Diabetes Mellitus (GDM)

  • Definition: Glucose intolerance of varying severity with initial onset or first clinical recognition occurring during pregnancy.

  • Maternal and fetal clinical risks:

    • Maternal risks: Preeclampsia, cesarean delivery, and increased long-term risk of developing permanent Type 2 diabetes postpartum.

    • Fetal and neonatal consequences:

    • Maternal hyperglycaemia results in persistent transplacental glucose transfer.

    • Fetal hyperglycaemia triggers compensatory pancreatic hypertrophy and fetal hyperinsulinemia.

    • Fetal hyperinsulinism drives excessive tissue growth and fat deposition, causing fetal macrosomia (birth weight >4 kg> 4\,\text{kg}).

    • Postnatal acute neonatal hypoglycaemia caused by persistent neonatal hyperinsulinemia upon cessation of maternal glucose supply via the umbilical cord.

    • Increased lifetime risk for developing childhood obesity and Type 2 diabetes in adult life.


Pathophysiology of gestational diabetes and fetal macrosomia
  • Clinical screening timeline and risk stratification:

    • High-risk pregnant women must be screened at their first prenatal visit:

    • Marked obesity.

    • Documented history of GDM in a previous pregnancy.

    • Presence of glycosuria.

    • Recurrent candidal vaginitis.

    • Strong family history of diabetes mellitus.

    • If initial early screening is negative, re-test between 24 weeks24\,\text{weeks} and 28 weeks28\,\text{weeks} of gestation.

  • Diagnostic thresholds in early pregnancy:

    • Fasting plasma glucose: >126 mg/dL> 126\,\text{mg/dL} (7.0 mmol/L7.0\,\text{mmol/L}).

    • Random plasma glucose: >200 mg/dL> 200\,\text{mg/dL} (11.1 mmol/L11.1\,\text{mmol/L}).

  • Diagnostic testing regimens for GDM:

    • One-step 75 g75\,\text{g} OGTT (fasting, 1 hour1\,\text{hour}, and 2 hour2\,\text{hour} measurements):

    • Fasting threshold: 95 mg/dL95\,\text{mg/dL}.

    • 1 hour1\,\text{hour} threshold: 180 mg/dL180\,\text{mg/dL}.

    • 2 hour2\,\text{hour} threshold: 155 mg/dL155\,\text{mg/dL}.

    • Two-step protocol with 100 g100\,\text{g} OGTT (fasting, 1 hour1\,\text{hour}, 2 hour2\,\text{hour}, and 3 hour3\,\text{hour} measurements):

    • Fasting threshold: 95 mg/dL95\,\text{mg/dL}.

    • 1 hour1\,\text{hour} threshold: 180 mg/dL180\,\text{mg/dL}.

    • 2 hour2\,\text{hour} threshold: 155 mg/dL155\,\text{mg/dL}.

    • 3 hour3\,\text{hour} threshold: 140 mg/dL140\,\text{mg/dL}.

    • Screening glucose challenge test (GCT):

    • Non-fasting administration of 50 g50\,\text{g} oral glucose load with plasma glucose measured at 1 hour1\,\text{hour}.

    • A result ≥140 mg/dL\ge 140\,\text{mg/dL} (7.7 mmol/L7.7\,\text{mmol/L}) warrants diagnostic progression to a formal multi-hour OGTT.

  • Postpartum follow-up recommendations:

    • Women diagnosed with GDM require lifelong screening for diabetes or prediabetes at least every 3 years3\,\text{years}.

    • Women with previous GDM identified with prediabetes must receive structured lifestyle modifications or pharmacological intervention (metformin) to mitigate Type 2 diabetes development.

Ancillary Laboratory Investigations

  • Serum Fructosamine:

    • Quantifies total glycated serum proteins, predominantly glycated serum albumin.

    • Because albumin has a biological circulating half-life of approximately 20 days20\,\text{days} (2 weeks2\,\text{weeks}), fructosamine reflects mean glycaemic exposure across the preceding 2−3 weeks2-3\,\text{weeks}.

    • Serves as a validated clinical alternative to HbA1c\text{HbA}_{1c} whenever red blood cell dynamics interfere with haemoglobin glycation, including:

    • Haemoglobinopathies.

    • Pregnancy (due to physiological plasma volume expansion and altered red cell turnover).

    • Advanced renal disease.

    • Analytical limitation: Results are dependent on baseline serum protein status; variations in serum albumin (e.g., hypoalbuminemia in nephrotic syndrome or cirrhosis) alter fructosamine measurements.

  • C-Peptide (Connecting Peptide):

    • A 31-amino-acid peptide cleaved from proinsulin in equimolar concentrations to mature insulin during packaging into beta